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Unlike most malignancies, chemotherapy but not surgery plays the most important role in treating non-Hodgkin
lymphoma (NHL). Currently, liposomes have been widely used to encapsulate chemotherapeutic drugs in treating
solid tumors. However, higher in vivo stability owns a much more important position for excellent antitumor efficacy in
treating hematological malignancies. In this study, we finely fabricated a rituximab Fab fragment-decorated liposome
based on 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), which can form intermolecular
cross-linking through the diacetylenic group by ultra-violet (UV) irradiation. Our experimental results demonstrated that
after the UV irradiation, the liposomes exhibit better serum stability and slower drug release with a decreased mean
diameter of approximately 285 nm. The cellular uptake of adriamycin (ADR) by this Fab-navigated liposome was
about four times of free drugs. Cytotoxicity assays against CD20+ lymphoma cells showed that the half maximal
(50%) inhibitory concentration (IC50) of ADR-loaded immunoliposome was only one fourth of free ADR at the
same condition. In vivo studies were evaluated in lymphoma-bearing SCID mice. With the high serum stability,
finely regulated structure, active targeting strategy via antigen-antibody reaction and passive targeting strategy
via enhanced permeability and retention (EPR) effect, our liposome exhibits durable and potent antitumor activities
both in the disseminated and localized human NHL xeno-transplant models.
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polymerizingBackground
Non-Hodgkin lymphoma (NHL) is a type of blood cancer,
which presents not only as a solid tumor of lymphoid cells
in lymph nodes and/or extranodal lymphatic organs such
as spleen and bone marrow, but also as free lymphoma cells
in circulating blood [1-3]. Particularly, most patients can be
cured with chemotherapy and/or radiation, which revealed
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in any medium, provided the original work is pof NHL [4-6]. Currently, while various chemotherapeutic
agents are validated to be effective in the treatment of
lymphoma in preclinical studies, clinical applications are
often limited for their side effects to normal tissues because
of the systemic administration. As a result, finding more ef-
fective strategy to maximize the curative effect while min-
imizing the side effects of chemotherapy against lymphoma
is of great importance and urgency [7,8].
In the past decade, nanocarriers, including liposomes,
polymeric nanoparticles, micelles, nanogels etc., with an
appropriate diameter of tens to hundreds of nanometers,
have received widespread attention for the specific deliv-
ery of bioactive reagents in the diagnosis and treatment
of cancer [7,9-12]. Encapsulation of bioactive reagents in
nanocarriers can result in significant accumulation andpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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drug in conventional formulations through the enhanced
permeability and retention (EPR) effect, which was firstly
described by Maeda and colleagues [13-17]. What's more,
the drug loading nanocarriers owns high serum stability,
which can contribute to long-time circulation in the blood
vessels, resulting in long-lasting antitumor activities, espe-
cially for the killing of free malignant cells in circulating
blood [12,17,18]. However, more and more laboratory
researches and clinical studies have demonstrated that
passive targeting strategy alone is not enough for more
sufficient and efficient accumulation of drug-loading
nanocarriers in some tumor types [19-21].
Following the FDA approval of anti-CD20 mAb Ritux-
imab for CD20+ NHL treatment, monoclonal antibody
(mAb)-based targeting therapy has revolutionized the treat-
ment of malignancies for the specific antitumor activity
and low cytotoxicity against normal tissues [22,23]. In
the last decade, more and more studies have confirmed
that the combination of mAb-based active targeting
and nanoparticle-based passive targeting can improve
drug concentration in tumor tissues and tumor cells in
a shorter time with greater accuracy [7,24,25].
In this study, we have developed an adriamycin (ADR)-
loaded liposome using the diacetylenic phosphatidylcholine
1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine
(DC8,9PC, hereafter referred to as PC), which can form
intermolecular cross-linking through the diacetylenic group
to produce a conjugated polymer within the hydrocar-
bon region of the bilayer by ultra-violet (UV) irradiation
(Additional file 1: Figure S1) [26,27]. For the sake of
active targeting, the Fab fragments of rituximab were
conjugated onto the liposomal surface. Our experimental
results demonstrate that this well-modified liposome, which
owns good serum stability and prolonged circulation time,
can accumulate in the tumor tissues and malignant cells
with high specificity and sufficient amount, which can bring
out exceptional excellent and durable therapeutic efficacy
against CD20-positive lymphomas.
Methods
Cell lines and materials
Two human B cell lymphoma cell lines, Raji and Daudi,
were obtained from the American Type Culture Collection
(ATCC). Cells were propagated and maintained in
RPMI 1640 supplemented with 10% (v/v) fetal bovine
serum (FBS, GIBCO, Invitrogen, Carlsbad, CA, USA)
in a controlled atmosphere incubator at 37°C with 5%
CO2. The DC8,9PC and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-
2000] (Mal-PEG) were purchased from Avanti Polar
Lipids (Williamsport, PA, USA). The anti-CD20 anti-
bodies rituximab was purchased from Roche (Basel,
Switzerland).Fabrication of Fab fragment-conjugated liposome (Figure 1)
Formation of drug-loaded liposomes
Total lipids mixtures of 2 mg DC8,9PC and 0.25 mg
Mal-PEG were dissolved in 500 μL mixed solvent of
chloroform and methyl alcohol with the volume ratio
at 1:1. Then, the solvent was evaporated under vortex
and flashed with nitrogen to obtain the lipid film,
followed by washing-out with 2 mL of ADR (doxorubicin
HCl, Melonepharma CO. LTD., Dalian, China) solution
(0.5 mg/mL in PBS) to obtain ADR-loaded multilamellar
vesicles [26]. The collected liposome solution was dialyzed
against PBS using a membrane (molecular weight cutoff
3 kDa) at 4°C for 12 h to remove uncombined ADR result-
ing in the ADR-loaded liposome stocking solutions.Thiolation of mAbs
The Fab fragment of rituximab was prepared as reported
previously [25]. Briefly, 10 mg/mL Rituximab was incu-
bated with 0.25 mg/mL de pepsin at 37°C overnight fol-
lowing with a centrifugation and dialysis against TBS
(145 mM NaCl and 10 mM Tris, pH 7.5) for 18 h. The
Staph A-Sepharose column (Pharmacia, Kalamazoo, MI,
USA) was used to remove the undigested mAbs at pH 8.0
resulting in the rituximab F(ab)2. The obtained F(ab)2
was further purified by the Sephadex G-150 column
(Pharmacia, MI, USA) which was pre-equilibrated by
the buffer 1 (0.1 M NaCl, 0.1 M borate, 0.05 M citrate and
2 mM EDTA, pH 5.5). Such F(ab)2 solution was concen-
trated to 10 mg/mL and further digested by the enzyme
papain. The Fab fragment solution was purified by the
same procedure as mentioned above resulting in the
single Fab fragment stocking solution storing at 4°C.
To activate the Fab fragments of rituximab for reactivity
toward the maleimide, the above stocking solutions were
incubated with 2-iminothiolane (2-IT, Sigma-Aldrich, St.
Louis, MO, USA) with a mass ratio of 1:0.15 (Fab/2-IT) at
room temperature for 2 h under a gentle shake. Unreacted
2-IT was removed by dialysis. The bovine serum albumin
(BSA) ~ SH was produced in the same way. The resulting
reactive Fab ~ SH and BSA ~ SH were stored at 4°C for
future usage [28].Fabrication of rituximab Fab-conjugated liposome
The Fab fragment-conjugated liposome was prepared
by coupling the reactive Fab ~ SH onto the liposomal
surface via the reaction between the ~ SH and Mal-group
at 4°C and N2 environment overnight; the un-conjugated
Fabs were removed by dialysis. The BSA-conjugated lipo-
some was fabricated in the same way. For UV irradiation,
pure liposome solutions were exposed to 20 irradiation
cycles at 4°C, with a 254-nm UV light dose of 360 mJ/cm2
per cycle using a Stratalinker-UV 1800 [26]. The concen-
tration of Fab fragments in the liposome solution was
Figure 1 Fabrication of rituximab Fab fragment-decorated liposomes.
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VueTM (GE Healthcare, Wilmington, MA, USA).
Characterization of Fab fragment-conjugated liposome
The hydrodynamic diameter and size distribution were
determined by ZetaSizer (Nano-ZS, Malvern Instruments,
Worcestershire, UK) equipped with a HeeNe laser (633 nm)
at the scattering angle 173°. To prepare stained specimens
for TEM (H-7000 Electron Microscope, Hitachi, Tokyo,
Japan) experiments, about 5 μL liposome solution was
dropped on 200-mesh Formvar-free carbon-coated copper
grids (Ted Pella Type-A; nominal carbon thickness 2 to
3 nm). After the water evaporating by exposing to air at
room temperature, the sample was inversely covered on a
small drop of hydrodated phosphotungstate (PTA) solu-
tion with a mass fraction of 2%. The conventional TEM
images were obtained at 100 kV.
Weight-average molecular weight analysis by SLS
The static light scattering (SLS) measurements were
carried out varying the scattering angle (θ) from 40 to
140° with a 5° stepwise increase [29]. The weight-average




R qð Þ ¼ 1 Mw þ 2A2C=
where K = [4π2n2(dn/dCP)
2]/NAVλ
4 is optical contrast,
with n being the refractive index of solvent, Cp the
liposomal concentration, dn/dCp the refractive index
increment against Cp determined by a double beam differ-
ential refraction meter (DMR-1021) (Otsuka Electronics,
Tokyo, Japan), λ the incident wavelength, and NAV the
Avogadro's number. R(q) is the Rayleigh ratio at a specific
measurement angle. By measuring R(q) for a set of θ andCp, values of Mw and A2 were estimated from typical
Zimm plots.
ADR releasing profile
A dialysis bag (molecular weight cutoff 1 kDa) containing
3 mL PC-ADR solution before or after UV irradiation was
respectively put in a beaker with 500 mL PBS. The beaker
was fixed in a water bath kept at 37°C with continues
siring. About 500 μL PBS solution outside the dialysis
bag was sampled at different time intervals, which was
measured by UV at 480 nm to determine the ADR con-
centration. The cumulative drug release was calculated
by the following function:
Cumulative release ¼ COutside dialysis bag  500 mL
CInside dialysis bag  3 mL  100%
Serum stability evaluation by DLS
For evaluating the effect of UV irradiation on the liposo-
mal stability, a bovine serum albumin (BSA) solution in
RPMI 1640 with a concentration of 50% (m/v) was used
as an in vitro serum model to mimic the in vivo status.
Then, the irradiation (irrad) and non-irrad liposome
solutions were separately mixed with the resulting
serum model at 37°C for 24 h. The dynamic light
scattering (DLS) was used to measure the size and size
distribution profile of BSA/liposome mixture at 0 and
24 h, respectively.
Cellular uptake and internalization assays
Raji and Daudi cells were seeded into a 48-well micro-
plate (1 × 105 cells) and incubated with 1 μg/mL free ADR,
ADR-loaded liposomes decorated with Fab fragments
(PC-ADR-Fab), or BSA (PC-ADR-BSA) in cell culture
medium containing 1% (v/v) antibiotics at 37°C for 4 h.
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negative control. After washing with PBS for twice, a
FACScan Flow Cytometer (Becton Dickinson, San Jose,
CA, USA) was used to assess the cellular uptake of
ADR or ADR-loaded liposomes by detecting the mean
fluorescence intensity (MFI) of FL-2 (ADR fluorescence).
Additionally, each sample was also visualized using an
inverse fluorescent microscopy.
In vitro cytotoxicity assay
Cytotoxicity assessment was carried out on Raji and Daudi
cells using a Cell Counting Kit-8 (CCK-8, Beyotime
Institute of Biotechnology, Shanghai, China) assay. Briefly,
cells were seeded in a 96-well plate at an initial density of
3,000 cells/well in 100 μL of RPMI-1640 supplemented
with 10% (v/v) heat-inactivated FBS, 1% (v/v) antibiotics,
and different concentrations of free ADR, PC-ADR-BSA,
or PC-ADR-Fab or the corresponding concentration of
rituximab Fab. After 48 h, 10 μL CCK-8 was added to
each well for another 2-h incubation protected from
light. The absorbance (Ab) at 450 nm was recorded by
a micro-plate reader (Thermo Multiskan MK3, Thermo
Scientific, Waltham, MA, USA), and cell viability was
calculated as the following function:
Cell viability% ¼ AbSample−AbBlank
 
AbControl−AbBlankð Þ  100%
where Absample, Abcontrol, and Abblank are the absorbance
values of each sample, the cells cultured in culture
medium without any additional substances, and the cul-
ture medium without cells in wells, respectively.
Animals
Healthy female SCID mice aged about 4 weeks were
purchased from Shanghai Experimental Animal Center
of Chinese Academic of Sciences (Shanghai, China), housed
in specific pathogen-free conditions, and treated in accord-
ance with guidelines of the Committee on Animals of
Changhai Hospital affiliated to the Second Military
Medical University (Shanghai China).
Pharmacokinetics and in vivo distribution analysis
The pharmacokinetics (PK) and in vivo distribution ana-
lysis was done following Joseph M. Tuscano's study with
minor revisions [31]. Briefly, Daudi cells (1 × 107) were
inoculated subcutaneously into the right flank of 6-
week-old SCID mice. For PK assays, when tumors
reached about 50 to 60 mm3 in volume (approximately
14 days), mice were randomly administrated tail vein in-
jection of free ADR, non-irrad or irrad ADR-containing
immunoliposomes at a dosage of 5 mg ADR/kg (n = 3
mice per treatment). Then, 10 μL of blood were col-
lected through tail vein nicking from each mouse at 5,15, and 30 min and 1, 2, 4, 6, 8, 12, 24, and 48 h after
treatment, respectively. Samples were immediately diluted
into 250 μL of 0.5 mmol/L EDTA-PBS, followed by a cen-
trifugation (300 g × 5 min). Plasma was collected and ADR
was extracted by acidified isopropanol (75 mmol/L hydro-
chloric acid in 90% isopropanol) at 4°C for 20 h. The ADR
concentrations were measured by UV at 480 nm and
expressed as micrograms per milliliter (ADR/blood
plasma). The data were analyzed by the PK solver software
[32]. For biodistribution assays, tumor-bearing mice were
randomly administrated tail vein injection of free ADR,
PC-ADR-BSA, or PC-ADR-Fab at a dosage of 5 mg ADR/
kg (n = 3 mice per treatment). Mice were sacrificed 24 h
after treatment; part of tumor, heart, liver, spleen, kidneys,
and lungs were removed, washed, and weighed; and
single-cell suspensions were made. ADR was extracted
from cells by the abovementioned acidified isopropanol
for 20 h at 4°C. The ADR concentrations were determined
as described above and expressed as micrograms per
gram (ADR/tissue). What's more, part of the tumor
tissues were collected and subjected to frozen sections,
which were detected by a confocal microscrope (Zeiss,
Oberkochen, Germany).
In vivo antitumor activity assessment in disseminated
human NHL xeno-transplant models
Six-week-old SCID mice were injected via the tail vein
with 5 × 106 Daudi cells in 100 μL PBS. Then, the inocu-
lated mice were randomly assigned to 4 groups with 10
each for the treatment of PBS, free ADR, PC-ADR-BSA,
and PC-ADR-Fab (with an equivalent amount of 5 mg/kg
ADR) via the tail vein weekly for 3 times after 48 h.
Post-operation monitoring was exercised at least once a
day until natural death in a range of 120 days. Survival
curves were plotted with the Kaplan-Meier method and
compared by using a log-rank test [33,34].
In vivo antitumor activity assessment in localized human
NHL xeno-transplant models
Daudi cells (1 × 107) in 100 μL of PBS buffer were inocu-
lated subcutaneously into the lateral flank of 6-week-old
SCID mice. When the tumors reached about 50 to
60 mm3 in volume, the inoculated mice were randomly
assigned to four groups with four each for the treatment
of PBS, free ADR, PC-ADR-BSA, and PC-ADR-Fab
(with an equivalent amount of 5 mg/kg ADR) via the tail
vein weekly for three times. Post-operation monitoring
was exercised at least once a day, and the tumor size
was measured in two perpendicular diameters with pre-
cision calipers every 3 days and calculated in a range of
60 days. Tumor volume was measured according to the
following formula [25]:
Tumor volume ¼ LengthWidth2=2
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shortest diameters of tumors, respectively.Statistical analysis
Data were expressed as the means ± standard deviation
(SD). Statistical analysis was performed by Student's t
test or one way ANOVA to identify significant differ-
ences unless otherwise indicated. Differences were
considered significant at a P value of <0.05.Results
Characterization of the liposome
It has been firmly established that size distribution of a
liposome strongly affect its in vitro and in vivo perfor-
mances [17,25]. Therefore, we firstly assessed the size
distribution of our liposome after the successful fabrica-
tion. Figure 2A shows the size distribution of irrad and
non-irrad liposomes. It was illustrated that an 11%
decrease in mean size was occurred after UV irradiation
(from approximately 321 nm before irradiation to 285 nm
after irradiation). This interesting physical change was
validated by morphology analysis using a TEM, of which
the results suggested that both the irrad and non-irradFigure 2 Properties of CD20 targeting liposomes. (A) Size distribution o
the liposomes before or after UV irradiation, scale bar 0.5 μm. (C) The drug
(D) The cytotoxicity profile of the empty liposomes PC-BSA and PC-Fab incliposome showed a regular spherical morphology with dif-
ferent diameters (Figure 2B).
Fab fragment loading
The number of Fab fragments per liposome was estimated
on the basis of Kozlowska's ideas according to the following
equation [35]: Fab fragments per liposome ¼ Fab molecules per mLliposomes per mL :
Firstly, the liposomal Mw was estimated to be 1.22 ×
107 g/mol by SLS analysis (Table 1), and the Fab con-
centration in liposome solution was quantified to be
52.2 μg/mL by determining the A260/A280 by Nano
VueTM. Besides, the total mass of liposomes in the sus-
pensions (total volume 2.85 mL) can be calculated from
the original polymer amount of 2 mg PC and 0.25 mg
Mal-PEG plus the detected amount of Fab (52.2 μg/mL ×
2.85 mL) to be approximately 2,398.8 μg. The total mass
of liposomes per milliliter can be calculated to be 841.7 μg
(2,398.8 μg/2.85 mL). Accordingly, we can estimate that
there are 6.9 × 10−11 mol [841.7 μg/(1.22 × 107 g/mol)] or
4.15 × 1013 liposomes per milliliter.
The number of Fab fragments (24 kDa) per milliliter
calculated in the same way was 2.2 × 10−9 mol [52.2 μg/
(2.4 × 104 g/mol)] or 1.3 × 1015. Hence we can estimate
that there are on average ~31.3 Fab fragments perf liposomes before or after UV irradiation. (B) The TEM morphology of
release profile of ADR-loaded liposomes before or after UV irradiation.
ubated with CD20 overexpressed Raji cells.
Table 1 Physicochemical parameters of ADR-loaded immunoliposomes
Rh (nm) PDI Mw (g/mol) Nagg Fab/liposome ADR (ng)/liposome
141.3 0.055 1.22 × 107 1,151 31.3 3.1 × 10−9
Rh, averaged radius; PDI, particle dispersion index; Mw, weight-average molecular weight; Nagg, the liposomal aggregation number; Fab/liposome, Fab fragments
per liposome; ADR/liposome, ADR mass per liposome.
Figure 3 Liposomal in vitro serum stability assessment. Up panel:
size distribution of the liposome dilution in RPMI 1640 containing 50%
(m/v) BSA. Down panel: size distribution of the above dilution after the
incubation at 37°C for 24 h. Red, liposomes before UV irradiation; black,
liposome after UV irradiation.
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somes), which is also shown in Table 1.
Drug loading and releasing properties
It was well expected that our liposome could be an
excellent drug carrier which benefits from the stable
structure following by self-assembling and UV irradi-
ation functions. For the validation of this expectation,
we firstly evaluated the ADR loading content (LC) of
our liposomes according to the following function:
Loading Content LCð Þ ¼ CADRCpolymer  100% . The results re-
vealed a relative high LC of 16.27% with our immunolipo-
somes. Besides, the amount of ADR per liposome was
estimated to be 3.1 × 10−9 ng (Table 1), which was calcu-
lated according to the following equation:
ADR=liposome ¼ ADR ngð Þ per mL=liposomes per mL
Also, the drug release profiles were determined in PBS
buffer at a PH value of 7.4 at 37°C. As expected (Figure 2C),
slower drug release from the irrad liposomes was observed
comparing with non-irrad liposomes. This controlled drug
release can be attributed to the polymerization of PC by
UV light irradiation. Otherwise, approximately 62%, 73%,
84%, 88%, and 91% of ADR was respectively released from
the irrad liposomes after 24, 48, 72, 96, and 120 h, the fact
of which ensures sufficient drug release at the tumor site,
especially in tumor cells.
Low cytotoxicity of liposomes
For the determination of the cytotoxicity, different concen-
trations of empty liposomes decorated by BSA (PC-BSA)
and rituximab Fab fragments (PC-Fab) were incubating
with Raji cells at 37°C for 48 h following by a CCK-8 detec-
tion. As illustrated in Figure 2D, both the PC-BSA and PC-
Fab showed low cytotoxicity to Raji cells in concentrations
of up to 32 μg/mL. It is worth mentioning that the cell
viability of PC-Fab-incubated cells had a little decrease
compared with PC-BSA-incubated cells, which may be
related with the weak tumor suppression effect of rituxi-
mab Fab fragments.
Serum stability evaluation
For future clinical applications, the in vivo stability of
liposome is another important factor which should be
considered. Therefore, we used the RPMI 1640 contain-
ing 50% BSA as an in vitro model of serum to check the
serum stability profile of our liposomes, in which theexistence of BSA was employed to mimic a variety of
serum proteins in the complicated environment within
the blood vessels. Figure 3 shows the size distribution of
liposome solutions before (red) and after (black) UV
irradiation. The first individual peak in each histogram
represents the size distribution of BSA, and the second
represents that of liposomes. The results indicated that
after the dilution of liposomes in serum model, the size
distribution of each sample was similar as separately
measured (Figure 3A), while after a 24-h incubation, the
well-separated peaks for BSA and liposomes still appeared
in the mixture, which is an indication of good serological
stability. However, the non-irrad liposomes in the mixture
showed a much broader size distribution (Figure 3B).
The results revealed that after the UV irradiation, our
liposomes showed better stability in the serum model
than non-irrad ones.
Intracellular uptake of liposomes
For the evaluation of intracellular uptake of our CD20-
targeting liposomes, the ADR-loaded liposomes, PC-
ADR-BSA and PC-ADR-Fab, were incubated with CD20+
Raji and Daudi cells for 4 h. After washing, the flow
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were used to evaluate the ADR fluorescence (red) in
lymphoma cells. As indicated by the mean fluorescence
intensity (MFI) of FL-2 (Figure 4A), the PC-BSA (green
hitograms) and PC-Fab (blue hitograms) significantly
enhanced the intracellular uptake of ADR compared
with free drugs (red hitograms) (**p = 0.000), while the
increasing extent of PC-Fab is much higher than that
of PC-BSA (**p = 0.000). This result was confirmed
by the inverse fluorescent microscopy as displayed in
Figure 4B.
In vitro cytotoxicity assays
The in vitro antitumor activities of our liposomes were
subsequently evaluated. After the incubation of Raji and
Daudi cells with different concentrations of free ADR,
rituximab Fab fragments, PC-ADR-BSA, and PC-ADR-
Fab for 48 h, a CCK-8 assay was employed to determine
the cell viability. As illustrated in Figure 5A,B, both Raji
and Daudi cells showed a significantly lower cell viability
after the treatment of drug-loaded liposomes compared
with free ADR, while PC-ADR-Fab exhibited more potent
antitumor activity compared with PC-ADR-BSA in all
the tested ADR concentrations. Because the therapeutic
effects of rituximab is largely dependent on the Fc-related
antibody-dependent cell-mediated cytotoxicity (ADCC)
and complement dependent cytotoxicity (CDC) [36], the
Fab fragments demonstrated low cytotoxicity in both
Raji and Daudi cells in all the tested concentrations
(0.005 to 1.3 μg/mL), which corresponded to the ADRFigure 4 Cellular uptake and intracellular accumulation of ADR-loade
panel: the histogram represents the fluorescence intensity distribution of R
treatment; green, PC-ADR-BSA treatment; blue, PC-ADR-Fab treatment. Dow
(MFI) of ADR fluorescence in Raji and Daudi cells. Data are mean ± SD of at
uptake indicated by the inverse fluorescent microscopy. Red fluorescence repconcentrations in the liposomal system. Furthermore,
the half maximal (50%) inhibitory concentration (IC50)
of ADR was calculated to evaluate the cytotoxicity of
the liposomal drug delivery systems according to the ADR
concentration dependence of the cell viability profile. It
was shown in Figure 5C that PC-ADR-Fab demonstrated
the lowest IC50 to Raji (0.103 μg/mL) and Daudi
(0.094 μg/mL) cells compared with PC-ADR-BSA (IC50Raji
0.208 μg/mL, IC50Daudi 0.229 μg/mL) and free ADR agents
(IC50Raji 0.436 μg/mL, IC50Daudi 0.441 μg/mL).Pharmacokinetics of ADR-containing liposomes in tumor
bearing SCID mice
After a short injection of free ADR and ADR-containing
liposomes at 5 mg/kg into lymphoma-bearing SCID mice,
the plasma ADR concentrations were measured at differ-
ent time intervals. The data were analyzed using the PK
solver software [32] and the results are all fitted to a
trilocular pattern [37]. The time-concentration curve is
shown in Additional file 2: Figure S2 and the PK parame-
ters in Table 2. As we can see, a remarkable difference in
plasma PK was observed after the tail vein administration
of free and liposomal ADR. The t1/2γ (the elimination half
time in the elimination phase) was relatively longer for irrad
liposomes (34.53 ± 2.63 h) than that for non-irrad lipo-
somes (21.13 ± 1.50 h) and free drugs (9.56 ± 4.06 h). In
contrast, the clearance (CL) was significantly reduced for
irrad liposomes (6.63 ± 3.74 ml/h versus CLnon-irrad liposomes
8.82 ± 4.54 ml/h, CLfree drugs 30.96 ± 5.86 ml/h).d liposomes. (A) Detection of ADR fluorescence intensity by FCM. Up
aji and Daudi cells. Black histogram, no-treat; red histogram, free ADR
n panel: Numerical data representing the mean fluorescence intensity
least three experiments. (B) The effects of liposomes on the intracellular
resents the intracellular ADR. Scale bar 50 μm.
Figure 5 In vitro antitumor activity of ADR loaded liposomes. Concentration-dependent cytotoxicity evaluation of free ADR, rituximab Fab,
PC-ADR-BSA, and PC-ADR-Fab in Raji cells (A) and Daudi cells (B). (C) The IC50 to Raji and Daudi cells of free ADR, PC-ADR-BSA, and PC-ADR-Fab.
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In order for in vivo distribution and tumor accumulation
assays, lymphoma-bearing SCID mice were injected with
free ADR and ADR-loaded liposomes (PC-ADR-BSA
and PC-ADR-Fab) via tail vein. Twenty-four hours after
treatment, tissues were harvested and the sum total
ADR was extracted and measured. Figure 6A shows
that there was a significant increase in tumor ADR
accumulation in PC-ADR-Fab compared with PC-ADR-
BSA (*p = 0.048) and free ADR-treated mice (**p = 0.000).
The heart, liver, spleen, and lungs all showed less ADR
accumulation with liposomal ADR treatment than with
free ADR treatment. There was no difference in ADR
accumulation among treatments for the kidneys. The
displayed fluorescent image of different frozen sectionsTable 2 Tumor bearing nude mice serum pharmacokinetic
parameters comparing free and liposomal ADRs (n = 3)
Parameter Unit Free ADR Non-irrad Irrad
t1/2α h 0.20 ± 0.02 0.19 ± 0.04 0.21 ± 0.05
t1/2β h 0.98 ± 0.19 3.89 ± 0.79 1.57 ± 1.31
t1/2γ h 9.56 ± 4.06 21.13 ± 1.50 34.53 ± 2.63
CL mL/h 30.96 ± 5.86 8.82 ± 4.54 6.63 ± 3.74
Cmax μg/mL 50.45 ± 5.54 54.13 ± 4.34 53.04 ± 5.68
AUC0-t (μg/mL) · h 79.97 ± 11.36 447.19 ± 54.19 713.49 ± 120.51
MRT h 6.37 ± 2.15 27.54 ± 1.53 48.58 ± 4.67
t1/2, the elimination half time; CL, clearance; Cmax, the maximum observed
concentration in the plasma; AUC, area under the concentration-time curve;
MRT, mean residence time.(Figure 6B) also demonstrated distinct enhancement of
red fluorescence in tumor tissues of mice treated with
ADR-loaded liposomes compared with that treated with
free ADR, and the administration of PC-ADR-Fab can
induce more retention of ADR in tumor tissues than
the administration of PC-ADR-BSA for the active target-
ing of Fab fragments.
In vivo antitumor activity assessment
For the evaluation of in vivo antitumor activities, both the
disseminated and localized human NHL xeno-transplant
models were set up. In the localized model, Daudi cells
were inoculated subcutaneously in the right flank of SCID
mice. When the tumors reached about 50-60 mm3 in
volume, mice were randomly treated with free ADR, PC-
ADR-BSA and PC-ADR-Fab with an equivalent ADR
amount of 5 mg/kg [25,38]. The mice were treated once
a week for SCID mice based on previous study and our
preliminary experimental results [39]. The tumor volume
was recorded and illustrated in Figure 6C. Our results
indicated that mice treated with PC-ADR-Fab and PC-
ADR-BSA demonstrated a remarkable decrease in tumor
burden compared with free ADR and control treatment
as measured by tumor volume. Otherwise, PC-ADR-Fab
exhibit a more excellent antitumor ability comparing with
PC-ADR-BSA, with 2/4 mice of complete remission (CR)
indicated by no measurable mass.
The excellent antitumor activity of our liposome is val-
idated using a disseminated model, in which Daudi cells
were transplanted intravenously into SCID mice via tail
Figure 6 In vivo antitumor activity of ADR-loaded liposomes. (A) Lymphoma-bearing SCID mice were treated with 5 mg/kg free ADR,
PC-ADR-Fab, and PC-ADR-Fab; 24 h later, mice were euthanized and organs were harvested, washed, and weighed; and the ADR was extracted and
quantified. (B) In vivo tumor accumulation profile of frozen section from lymphoma-bearing SCID mice treated with free ADR, PC-ADR-BSA, and
PC-ADR-Fab for 24 h as visualized by confocal microscopy, the RED fluorescence represents the tumor accumulation and retention of ADR. Scale
bar 50 μm. (C) In vivo anticancer therapeutic effects in localized human NHL xeno-transplant models after the first intravenous administration of
PBS, free ADR, PC-ADR-BSA, and PC-ADR-Fab. Tumor volumes were measured every 3 days. Results are presented as mean ± SD of four separate
mice in one group.→, treatment. (D) In vivo antitumor therapeutic effects in disseminated human NHL xeno-transplant models after the first
intravenous administration of PBS, free ADR, PC-ADR-BSA, and PC-ADR-Fab. Survival curves were plotted with the Kaplan-Meier method and were
compared by using a log-rank test.
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injections of PBS, free ADR, PC-ADR-BSA, and PC-
ADR-Fab for three times once a week. Survival curves
were plotted with the Kaplan-Meier method and were
compared by using a log-rank test [33,34]. As illustrated
in Figure 6D, ADR-loaded liposome (PC-ADR-BSA
and PC-ADR-Fab) treatment significantly prolonged
the survival of tumor-bearing mice compared to free
ADR and PBS control treatment (*p < 0.05). As our ex-
pectation, comparing with PC-ADR-BSA treatment,
the administration of PC-ADR-Fab led to significant
prolongation of graft survival days (*p < 0.05), with a
CR percentage of 4/10 indicated by long-term survival
(>120 days post-treatment).
Discussion
NHL presents not only as a solid tumor of lymphoid cells
in lymph nodes and/or extranodal lymphatic organs, but
also as free lymphoma cells in circulating blood [1-3].
Unlike most other malignancies, chemotherapy but notsurgery plays the most important role in curing NHL
[4-6]. Currently, more and more studies are focusing
on finding out novel drug delivery system for treating
solid tumors [7,11,17,25]. However, for the elimination
of free malignant cells in circulating blood, high serum
stability and specificity to tumor cells are of great
importance.
In this study, we have successfully fabricated a rituximab
Fab-conjugated liposome based on PC, of which the
well-defined spherical morphology was observed under
TEM. Because PC is a kind of diacetylenic lipids, which can
form intermolecular cross-linking through the diacetylenic
group by UV irradiation to form chains of covalently linked
lipids in the liposomal bilayers (Additional file 1: Figure S1)
[26], this covalently union between lipid chains leads to
a relatively more compact structure; thus, an important
impact on the stability of the polymerized drug delivery
system can be obtained. This enhanced serum stability
can result in longer-time circulation and slower clearance
of encapsulated drugs in vivo. Further experimental results
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some. All the abovementioned properties are of vital
importance for an ideal drug delivery system in elimin-
ating malignant lymphoma cells, especially those in the
peripheral blood.
In order to determine the antitumor activities, we took
two lymphoma cell lines, Raji and Daudi, as study targets.
The experimental results demonstrated that the in vitro
cytotoxicity of ADR-loaded targeting liposome (PC-ADR-
Fab) was significantly promoted due to the enhancement of
drug uptaking compared with free drugs and ADR-loaded
non-targeting liposome. The result may be ascribed to the
following two reasons. Firstly, previous studies have proven
that nanoparticles are taken up by cells via clathrin
and/or caveoli-mediated endocytosis unlike small mol-
ecule drugs, which were taken up by passive diffusion
[40,41]. Thus, most nanoparticles can obviously enhance
the intracellular uptake of chemotherapeutic agents, which
was confirmed by previous studies and recognized as an
important advantage of nanosized drug delivery system
[25,42,43]. Secondly, the intracellular uptake could be
further improved by the Fab fragments of rituximab
based on the active targeting strategy by antigen-antibody
identification and combination.
In vivo experimental results indicated that the immu-
noliposomes are selectively accumulated in tumor tissues,
while the administration of free drugs resulted in high
concentration of ADR in either normal or malignant
tissues with no specificity. This remarkable discrepancy
can significantly improve the bioavailability and reduce
the detrimental cytotoxicity of chemotherapeutic agents.
The in vivo antitumor experiments carried out both in
the localized and disseminated human NHL xeno-
transplant models suggest that our immunoliposome
was significantly more effective than either free ADR or
non-targeting liposomal ADR in inhibiting primary tumor
growth and prolonging the graft survival. What's more,
our immunoliposome still showed great advantage in
tumor suppressing efficacy when compared with other
drug delivery systems. For example, comparing with the
anti-CD30 antibody-conjugated liposomal doxorubicin
constructed by Ommoleila Molavi et al., the treatment
of which can respectively decrease the tumor burden to
approximately 1/7 and approximately 1/2 in comparison
with PBS and free ADR treatment [44]; our immunoli-
posome can remarkably decrease the tumor burden to
approximately 1/14 and approximately 1/4, respectively.
In our opinion, this exceptional excellent in vivo antil-
ymphoma activity of the ADR-loaded Fab fragment-
decorated liposome is the cooperative action of the
following effects: (1) enhanced intracellular uptake due
to effective endocytosis based on well-defined liposomal
structure and size distribution; (2) enhanced serum stability
and controlled drug release (as a result of UV irradiationpolymerizing) can contribute to long circulation time and
durable antilymphoma activity; (3) enhanced tumor accu-
mulation and retention in vivo through dual targeting
function, passive targeting through EPR effects and active
targeting through antigen-antibody reaction.
Conclusions
In this study, we have identified a novel liposomal drug
delivery system, PC-Fab, for improved chemotherapy of
CD20-positive NHL. The in vitro and in vivo experimental
results clearly suggested that this Fab fragment-decorated
liposome can be a promising weapon in combating NHL,
which deserves further investigation for clinical application.
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